Skip to content

Oculomotor Assessment of Traumatic Brain Injury (TBI)

Oculomotor Assessment of Traumatic Brain Injury (TBI)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03156010
Enrollment
201
Registered
2017-05-16
Start date
2017-09-18
Completion date
2023-04-19
Last updated
2023-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury

Keywords

oculomotor testing

Brief summary

The purpose of the proposed study is to compare the sensitivity and specificity of three oculomotor test devices in normal subjects versus subjects with history of TBI. The study is designed as a prospective research project in which a group of 120 normal controls without a history of TBI will be compared to another group of 120 participants (total of 240) who have a confirmed history of TBI. Each participant will complete the TBI assessment protocol for each of three separate devices (Neuro Kinetics, SyncThink, and Oculogica). The order of the devices will be counter-balanced across participants. Participants will also be screened for vestibular migraine and visual vertigo, which are two conditions that influence oculo-vestibular perception in normal and TBI patients and might influence the results from the three oculomotor devices. Data from each device will be utilized to perform AUC analyses to determine the respective sensitivity and specificity for each.

Interventions

DEVICENeuro Kinetics IPAS

Testing with PAS device

DEVICEOculogica EyeBox

Testing with Oculogica EyeBox device

DEVICESyncThink EyeSync Device

Testing with SyncThink EyeSync device

Sponsors

Neurolign
CollaboratorINDUSTRY
Sync-Think, Inc.
CollaboratorINDUSTRY
Oculogica, Inc.
CollaboratorINDUSTRY
TBICoE
CollaboratorUNKNOWN
United States Department of Defense
CollaboratorFED
Walter Reed National Military Medical Center
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

All participants undergo testing with the same three devices. The order of devices will be semi-randomized to eliminate order effects.

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

All participants must be DEERS eligible, no exceptions! Inclusion Criteria: * Must be between 18 and 45 at time of screening (upper age restriction is to prevent confounding with age-related physiological changes). * Must be able to provide written informed consent. * Must be able to read and understand questionnaires and consent forms. * Must have corrected binocular acuity of at least 20/40 for near distance with or without single-power corrective lenses or contacts and absent of ocular injury or disease. Control Group - No history of TBI or any history of severe or penetrating TBI TBI Group - Must have a documented history of a TBI occurring within the last 10 years.

Exclusion criteria

* Current or previous neurological disease, including: stroke, congenital brain malformation, degenerative illness such as multiple sclerosis, epilepsy or seizure (other than febrile seizure). * Current or previous ocular disease/injury, including: Glaucoma or increased pressure in the eyes, structural damage to ocular tract and ocular cortex, etc. * History of vestibular disorder (e.g., with symptoms of clinical vertigo) * Binocular vision not correctable to 20/40 for near distance * Use of tobacco or caffeinated products less than four hours before test session * Consumption of alcohol within past 24 hours

Design outcomes

Primary

MeasureTime frameDescription
Area Under the Curve (AUC)Single test session (1.5 hours) - all testing performed at time of study enrollment, will be reported at conclusion of data collection as all data is required to generate AUCs.Determination of sensitivity/specificity measure for each device using known characteristics of arms (i.e., history of TBI vs no history of TBI)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026